SLDB
HealthcareSolid Biosciences Inc. · Biotechnology · $520M
What is Solid Biosciences Inc.?
Solid Biosciences is a clinical-stage biotechnology company focused exclusively on developing gene therapies for Duchenne muscular dystrophy (DMD), a severe and progressive muscle-wasting disease. The company is headquartered in Cambridge, Massachusetts.
Solid Biosciences advances gene transfer candidates designed to restore functional dystrophin protein expression in the muscles of DMD patients. Its lead program, SGT-001, is being evaluated in a Phase I/II clinical trial, while next-generation candidate SGT-003 represents a further evolution of its approach. The company also develops platform technologies — including dual gene expression and novel capsid designs — and holds a collaboration and license agreement with Ultragenyx Pharmaceutical to advance DMD gene therapies.
Solid Biosciences was incorporated in 2013 and is based in Cambridge, Massachusetts.
- SGT-001: lead gene transfer candidate in Phase I/II clinical trial for DMD
- SGT-003: next-generation gene transfer candidate for Duchenne muscular dystrophy
- Dual gene expression platform for packaging multiple transgenes into one vector
- Novel capsid technology development for improved gene delivery
- Collaboration with Ultragenyx Pharmaceutical for DMD gene therapy programs
Is SLDB a Good Stock to Buy?
UQS Score rates SLDB as Poor overall, reflecting the early-stage nature and significant uncertainties of the business.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's near-term financial structure carries less immediate distress than many clinical-stage peers. Valuation is labeled Elevated, which in this context reflects the speculative premium the market places on pipeline potential rather than current fundamentals.
Quality, Moat, and Growth all register as Weak — consistent with a pre-revenue biotech that has yet to establish a commercial product, durable competitive advantages, or a demonstrated growth trajectory.
Pro members can view the complete pillar breakdown and underlying financial metrics for SLDB on the full analysis page. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SLDB pay dividends?
No — Solid Biosciences Inc. does not currently pay a dividend.
Solid Biosciences does not pay a dividend. As a clinical-stage company with no commercial revenue, capital is directed toward research, clinical trials, and pipeline development. Income-focused investors should not expect distributions from SLDB in the near term, as reinvestment into the DMD program remains the company's primary use of available resources.
When does SLDB report earnings?
Solid Biosciences reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage biotech, SLDB's quarterly reports center on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and collaboration updates tend to drive investor attention around each reporting period.
For the most recent quarter's results and management commentary, visit Solid Biosciences' investor relations page directly.
SLDB Price History
-85.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Solid Biosciences Inc.?
Based on Solid Biosciences Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SLDB Long-term Outlook
The fundamental outlook for SLDB is shaped heavily by clinical execution risk. With Growth and Quality both rated Weak, the path to value creation runs almost entirely through successful clinical trial readouts for SGT-001 and advancement of SGT-003. The Ultragenyx collaboration provides some external validation, but the Risk pillar — while rated Good relative to peers — does not eliminate the binary nature of clinical-stage biotech investing. Elevated Valuation suggests the market has already priced in meaningful pipeline optionality.
Growth drivers
- Clinical advancement of SGT-001 toward potential regulatory milestones
- Pipeline expansion through SGT-003 and novel capsid platform technologies
- Ultragenyx collaboration providing resources and development expertise
Key risks
- Clinical trial failure or safety signals could materially impair the company's value
- Pre-revenue status means ongoing dependence on external financing
- Elevated valuation leaves limited margin of safety if pipeline progress stalls
SLDB vs Peers
Solid Biosciences operates in a competitive rare-disease and gene therapy landscape alongside several other small-cap clinical-stage companies.
BioAge focuses on aging biology and metabolic disease rather than DMD, representing a distinct therapeutic area within the rare-disease biotech space.
Eton targets rare pediatric diseases with a commercial-stage model, giving it a different revenue profile compared to SLDB's pre-revenue pipeline focus.
Prime Medicine develops prime editing gene correction technologies across multiple disease areas, competing broadly in the next-generation gene therapy platform space.
Frequently Asked Questions
What does Solid Biosciences do?
Solid Biosciences is a clinical-stage biotechnology company developing gene therapies for Duchenne muscular dystrophy. Its programs aim to restore functional dystrophin protein in patients' muscles through gene transfer technology. The company also develops enabling platform technologies and has a collaboration agreement with Ultragenyx Pharmaceutical.
Does SLDB pay dividends?
No, Solid Biosciences does not pay a dividend. The company is pre-revenue and directs its capital toward clinical development and research. Investors seeking income distributions should look elsewhere, as dividend payments are not part of SLDB's current financial strategy.
When does SLDB report earnings?
Solid Biosciences reports on a quarterly cadence, as is standard for US-listed companies. Because it is a clinical-stage biotech, reports focus on cash position, operating expenses, and pipeline updates rather than revenue. Check the company's investor relations page for the current reporting schedule.
Is SLDB a good stock to buy?
UQS Score rates SLDB as Poor overall, with Weak scores across Quality, Moat, and Growth pillars. The Risk pillar is the relative standout. This profile reflects the high uncertainty typical of pre-revenue clinical-stage biotechs. Pro members can access the full pillar breakdown to inform their own research.
Is SLDB overvalued?
UQS Score labels SLDB's Valuation as Elevated. For a pre-revenue biotech, this typically reflects speculative pipeline premium rather than earnings-based valuation. Elevated valuation in this context means there is limited margin of safety if clinical milestones are delayed or missed.
How does SLDB compare to its competitors?
SLDB competes in the small-cap rare-disease and gene therapy space alongside companies like BioAge Labs, Eton Pharmaceuticals, and Prime Medicine. Each pursues different therapeutic areas or platform approaches. The UQS Score comparison tool available to Pro members shows how SLDB's pillar ratings stack up against these peers.
What is SLDB's market cap bracket?
Solid Biosciences is classified as a small-cap company. This places it in a category where liquidity can be lower and share price volatility higher than large- or mega-cap peers, which is common among clinical-stage biotechs with no commercial revenue.
Who founded Solid Biosciences?
Solid Biosciences was founded by a group that included individuals personally connected to the Duchenne muscular dystrophy community, reflecting the company's mission-driven origins. Founding details are publicly available through the company's official disclosures and investor relations materials.
Is SLDB a long-term quality investment?
As a long-term quality indicator, UQS Score rates SLDB as Poor, with Weak readings across Quality, Moat, and Growth. Long-term quality investing typically favors companies with durable competitive advantages and consistent financial performance — characteristics SLDB has not yet established as a pre-revenue clinical-stage company.
What is the main competitive advantage of Solid Biosciences?
Solid Biosciences' potential advantage lies in its focused DMD gene therapy pipeline and proprietary platform technologies, including dual gene expression and novel capsid designs. However, UQS Score currently rates its Moat as Weak, reflecting that no durable commercial advantage has yet been established.
What sector does SLDB belong to?
Solid Biosciences operates in the Healthcare sector, specifically within clinical-stage biotechnology focused on rare genetic diseases. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader sector context.
Is SLDB a growth stock or value stock?
Based on UQS pillar labels, SLDB carries an Elevated Valuation and a Weak Growth rating — an unusual combination that reflects speculative pipeline pricing without demonstrated revenue growth. It does not fit neatly into either the traditional growth or value category at this stage.
Unlock Full SLDB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS Score and all five pillar scores
- ✓Access detailed financial metrics and trend data
- ✓Compare SLDB side-by-side with sector peers
- ✓See the complete Quality, Moat, and Risk breakdown
- ✓Track score changes as new data is released
- ✓Filter small-cap healthcare stocks by pillar strength
Pro Analysis
SLDB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 15.4 | 0.0 | 10.0 | 18.5 | 61.6 | 0.0 | -1.8 |
| Apr 22, 2026 | 17.2 | 0.0 | 10.0 | 18.5 | 73.1 | 0.0 | -0.9 |
| Apr 14, 2026 | 18.1 | 0.0 | 10.0 | 23.1 | 73.1 | 0.0 | -10.0 |
| Apr 13, 2026 | 28.1 | 0.0 | 50.0 | 23.1 | 73.1 | 0.0 | +10.0 |
| Apr 2, 2026 | 18.1 | 0.0 | 10.0 | 23.1 | 73.1 | 0.0 | — |
SLDB — Pillar Breakdown
Quality
— 0.0/100 (25%)Solid Biosciences Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Solid Biosciences Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 61.6/100 (15%)Solid Biosciences Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Solid Biosciences Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 10/100 (25%)Solid Biosciences Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SLDB.
Score Composition
Financial Data
More Stock Analysis
How is the SLDB UQS Score Calculated?
The UQS (Unified Quality Score) for Solid Biosciences Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Solid Biosciences Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Solid Biosciences Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.